| References: |
LDN193189(DM 3189) is a selective BMP signaling inhibitor, inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively, exhibits 200-fold selectivity for BMP versus TGF-β.LDN193189 potently inhibits BMP4-mediated Smad1, Smad5 and Smad8 activation with IC50 of 5 nM, and efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively. Furthermore, LDN193189 also shows the inhibitory effect on the transcriptional activity induced by either constitutively active ALK2R206H or ALK2Q207D mutant proteins . A recent study shows that LDN-193189 blocks the production of reactive oxygen species induced by oxidized LDL during atherogenesis in human aortic endothelial cells For the detailed information of LDN193189 free base, the solubility of LDN193189 free base in water, the solubility of LDN193189 free base in DMSO, the solubility of LDN193189 free base in PBS buffer, the animal experiment (test) of LDN193189 free base, the cell expriment (test) of LDN193189 free base, the in vivo, in vitro and clinical trial test of LDN193189 free base, the EC50, IC50,and affinity,of LDN193189 free base, Please contact DC Chemicals. |
